PL2617734T3 - Ludzkie przeciwciała przeciwko TSHR - Google Patents
Ludzkie przeciwciała przeciwko TSHRInfo
- Publication number
- PL2617734T3 PL2617734T3 PL13163955T PL13163955T PL2617734T3 PL 2617734 T3 PL2617734 T3 PL 2617734T3 PL 13163955 T PL13163955 T PL 13163955T PL 13163955 T PL13163955 T PL 13163955T PL 2617734 T3 PL2617734 T3 PL 2617734T3
- Authority
- PL
- Poland
- Prior art keywords
- human anti
- tshr antibodies
- anti tshr
- antibodies
- human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0823562A GB0823562D0 (en) | 2008-12-24 | 2008-12-24 | Antibodies |
| GB0908945A GB0908945D0 (en) | 2009-05-22 | 2009-05-22 | Antibodies |
| EP09795799.7A EP2367850B1 (en) | 2008-12-24 | 2009-12-23 | Human anti tshr antibodies |
| EP13163955.1A EP2617734B1 (en) | 2008-12-24 | 2009-12-23 | Human anti tshr antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2617734T3 true PL2617734T3 (pl) | 2016-01-29 |
Family
ID=41683030
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL13163955T PL2617734T3 (pl) | 2008-12-24 | 2009-12-23 | Ludzkie przeciwciała przeciwko TSHR |
| PL09795799T PL2367850T3 (pl) | 2008-12-24 | 2009-12-23 | Ludzkie przeciwciała przeciwko TSHR |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL09795799T PL2367850T3 (pl) | 2008-12-24 | 2009-12-23 | Ludzkie przeciwciała przeciwko TSHR |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9073992B2 (pl) |
| EP (3) | EP2617735A3 (pl) |
| JP (2) | JP5784504B2 (pl) |
| CN (2) | CN104829721B (pl) |
| ES (2) | ES2540538T3 (pl) |
| PL (2) | PL2617734T3 (pl) |
| WO (1) | WO2010073012A2 (pl) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1456234B1 (en) * | 2001-08-23 | 2014-04-09 | Rsr Limited | Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| PL2121758T3 (pl) * | 2007-02-15 | 2015-02-27 | R S R Ltd | Ludzkie przeciwciała monoklonalne przeciwko receptorowi tyreotropiny, które działają jako antagoniści |
| JP5908590B2 (ja) * | 2011-09-09 | 2016-04-26 | クイデル コーポレーション | 自己抗体を検出するための組成物および方法 |
| GB2527286A (en) * | 2014-06-11 | 2015-12-23 | Rsr Ltd | Glycoprotein hormone receptor mutations |
| CN109219445B (zh) | 2016-04-01 | 2022-08-26 | 上海煦顼技术有限公司 | 嵌合抗原受体修饰细胞治疗癌症的应用 |
| US10654934B2 (en) | 2016-04-01 | 2020-05-19 | Innovative Cellular Therapeutics CO., LTD. | Use of chimeric antigen receptor modified cells to treat cancer |
| US20220227875A1 (en) * | 2019-05-31 | 2022-07-21 | University Of Florida Research Foundation, Incorporated | Vector-based therapy for thyroid disease |
| CN115298213A (zh) | 2019-12-19 | 2022-11-04 | 奎多公司 | 单克隆抗体融合 |
| CN111647624A (zh) * | 2020-06-10 | 2020-09-11 | 成都和同易创生物科技有限公司 | Tsab人源单克隆抗体重组载体、重组抗体及其制备方法 |
| US20240415888A1 (en) * | 2021-10-20 | 2024-12-19 | Memorial Sloan Kettering Cancer Center | Anti-tshr multi-specific antibodies and uses thereof |
| CN114113637B (zh) * | 2021-12-07 | 2024-03-12 | 郑州安图生物工程股份有限公司 | 一种促甲状腺激素受体抗原试剂及促甲状腺激素受体抗体定量检测试剂盒 |
| JP2025529812A (ja) * | 2022-08-31 | 2025-09-09 | シャンハイ シーゼン メディカル テクノロジー カンパニー リミテッド | 甲状腺刺激ホルモン受容体に結合する抗体及びその使用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US20250388688A1 (en) * | 2024-04-04 | 2025-12-25 | Ethyreal Bio, Inc. | Anti-tshr antibodies and uses thereof |
| WO2026028159A1 (en) | 2024-07-31 | 2026-02-05 | Biohaven Therapeutics Ltd. | Bifunctional degraders for the treatment of graves' disease |
| WO2026044000A1 (en) | 2024-08-20 | 2026-02-26 | Ethyreal Bio, Inc. | Multispecific antibodies and methods of use thereof |
| CN119462926A (zh) * | 2024-09-27 | 2025-02-18 | 兰州大学第二医院 | 一种抗促甲状腺激素受体单克隆抗体1a4及应用 |
| CN118897090B (zh) * | 2024-09-30 | 2025-06-06 | 美康生物科技股份有限公司 | 一种刺激性促甲状腺激素受体抗体亚型检测试剂盒及其制备方法与应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4697820B2 (ja) * | 1998-08-31 | 2011-06-08 | 宝ホールディングス株式会社 | 醸造酒の製造方法 |
| JP2000236882A (ja) * | 1999-02-24 | 2000-09-05 | Shionogi & Co Ltd | マウスナース細胞レセプター遺伝子 |
| DE10130657A1 (de) | 2001-06-27 | 2003-01-16 | Axaron Bioscience Ag | Neues endothetial exprimiertes Protein und seine Verwendung |
| EP1456234B1 (en) * | 2001-08-23 | 2014-04-09 | Rsr Limited | Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto |
| JP2003125780A (ja) * | 2001-10-22 | 2003-05-07 | Mitsubishi Pharma Corp | 新規ｇｐｃｒ、それをコードする遺伝子及びそれらの用途 |
| EP2383296B1 (en) * | 2002-11-29 | 2017-02-22 | Rsr Limited | Antibody for the thyrotropin receptor and uses thereof |
| GB0418181D0 (en) | 2004-08-13 | 2004-09-15 | Rsr Ltd | Thyrotrophin receptor preparations,thyrotrophin receptor epitopes,antibody and hormone interactions therewith,and uses thereof |
| US20080305098A1 (en) * | 2005-11-21 | 2008-12-11 | Dr. Fenning Biomed Gmbh | Recombinant Polypeptides and Methods for Detecting and/or Quantifying Autoantibodies Against Tsh Receptor |
| JP5165672B2 (ja) * | 2006-03-29 | 2013-03-21 | キングス カレッジ ロンドン | Ｔｓｈｒに対するアゴニスト抗体 |
| US8097699B2 (en) | 2006-08-30 | 2012-01-17 | Rsr Limited | Crystal structure of thyroid stimulating hormone receptor |
| US8350012B2 (en) | 2007-01-25 | 2013-01-08 | Cedars-Sinai Medical Center | Inverse agonist monoclonal antibody that suppresses thyrotropin receptor constitutive activity |
| PL2121758T3 (pl) * | 2007-02-15 | 2015-02-27 | R S R Ltd | Ludzkie przeciwciała monoklonalne przeciwko receptorowi tyreotropiny, które działają jako antagoniści |
-
2009
- 2009-12-23 US US13/142,217 patent/US9073992B2/en active Active
- 2009-12-23 EP EP13163959.3A patent/EP2617735A3/en not_active Withdrawn
- 2009-12-23 PL PL13163955T patent/PL2617734T3/pl unknown
- 2009-12-23 ES ES09795799.7T patent/ES2540538T3/es active Active
- 2009-12-23 EP EP13163955.1A patent/EP2617734B1/en active Active
- 2009-12-23 PL PL09795799T patent/PL2367850T3/pl unknown
- 2009-12-23 EP EP09795799.7A patent/EP2367850B1/en active Active
- 2009-12-23 WO PCT/GB2009/002946 patent/WO2010073012A2/en not_active Ceased
- 2009-12-23 ES ES13163955.1T patent/ES2545759T3/es active Active
- 2009-12-23 CN CN201510226986.9A patent/CN104829721B/zh active Active
- 2009-12-23 JP JP2011542893A patent/JP5784504B2/ja active Active
- 2009-12-23 CN CN200980152452.9A patent/CN102264764B/zh active Active
-
2015
- 2015-07-02 US US14/790,489 patent/US10428153B2/en active Active
- 2015-07-22 JP JP2015144729A patent/JP5978360B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2367850A2 (en) | 2011-09-28 |
| US9073992B2 (en) | 2015-07-07 |
| JP5784504B2 (ja) | 2015-09-24 |
| ES2545759T3 (es) | 2015-09-15 |
| WO2010073012A3 (en) | 2010-08-19 |
| CN102264764B (zh) | 2015-06-10 |
| EP2617734A1 (en) | 2013-07-24 |
| EP2617735A3 (en) | 2013-10-16 |
| EP2617735A2 (en) | 2013-07-24 |
| JP2016034934A (ja) | 2016-03-17 |
| US20110300138A1 (en) | 2011-12-08 |
| US10428153B2 (en) | 2019-10-01 |
| PL2367850T3 (pl) | 2015-12-31 |
| CN102264764A (zh) | 2011-11-30 |
| ES2540538T3 (es) | 2015-07-10 |
| JP5978360B2 (ja) | 2016-08-24 |
| EP2367850B1 (en) | 2015-04-22 |
| US20150344582A1 (en) | 2015-12-03 |
| WO2010073012A2 (en) | 2010-07-01 |
| EP2617734B1 (en) | 2015-07-15 |
| CN104829721B (zh) | 2018-06-19 |
| JP2012513747A (ja) | 2012-06-21 |
| CN104829721A (zh) | 2015-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2367850T3 (pl) | Ludzkie przeciwciała przeciwko TSHR | |
| AP3371A (en) | Anti-IGF antibodies | |
| PL2949666T3 (pl) | Ludzkie przeciwciała przeciwko alfa-synukleinie | |
| IL207217A0 (en) | Humanized anti-c5ar antibodies | |
| PL2262831T4 (pl) | Przeciwciała przeciwko properdynie | |
| EP2331579A4 (en) | MONOCLONAL ANTIBODIES | |
| GB0821100D0 (en) | Antibodies | |
| IL214827A0 (en) | Bispecific anti-her antibodies | |
| EP2374883A4 (en) | ANTI-CD4 ANTIBODIES | |
| SG10201601279SA (en) | Monoclonal Antibody STRO-4 | |
| IL217919A0 (en) | Humanized anti-cdcp1 antibodies | |
| ZA201202227B (en) | Monoclonal antibodies | |
| IL207581A0 (en) | Anti-tyrp1 antibodies | |
| ZA201202793B (en) | Humanized antibodies against human il-22ra | |
| GB0905972D0 (en) | Antibodies against IL-17BR | |
| IL212795A0 (en) | Fully human antibodies against n-cadherin | |
| ZA201007976B (en) | Anti-pirb antibodies | |
| GB0815788D0 (en) | Therapeutic antibodies | |
| GB0818356D0 (en) | Antibodies | |
| EP2324059A4 (en) | THERAPEUTIC ANTI-PAMP ANTIBODIES | |
| HRP20190159T1 (hr) | Antitijela humanog anti-alfa-sinukleina | |
| GB0823562D0 (en) | Antibodies | |
| GB0806230D0 (en) | Antibodies | |
| GB0804687D0 (en) | Humanized antibody | |
| GB0804686D0 (en) | Humanized antibody |